Insider trade report
Open the filing on sec.gov
Larimar Therapeutics, Inc. (LRMR)
Nasdaq: LRMR · Pharmaceutical Preparations · Bala Cynwyd, PA · filing with the SEC since 2006
The companyfiscal 2019, as filed
Revenue$0.00
Net income-$23.1M+62.3%
Earnings per sharen/a
Operating cash flow-$22.7M+55.9%
Cash$1.0M-98.0%
Debt$14.5M-27.3%
Shareholders’ equity-$694,000-123.8%
Shares, dilutedn/a
Return on equity-212.2%
The recordfrom its filings
Filings in 202650
Newest filingNov 12 · 4
Annual reportMar 19, 2026
Quarterly reportAug 4, 2026
Next report due10-Q by Nov 14
Insider sales, 12 months$0.00
Insider buys, 12 months$26.1M
Patents granted55
Filer categoryNon-accelerated filer<br>Smaller reporting company
Trailing twelve months to Jun 2026Net income -$173Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Results released
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider holding, initial
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.